Related Experiment Video

Updated: Feb 20, 2026

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment
11:13

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Published on: June 9, 2023

2.4K

Inhibition of AKT survival pathway by a small molecule inhibitor in human endometrial cancer cells

X Jin1, D R Gossett, S Wang

  • 1Department of Pathology, University of Michigan Comprehensive Cancer Center, Ann Arbor, MI, USA.

British Journal of Cancer
|October 27, 2004
PubMed

Insights

PTEN mutations in endometrial cancer activate AKT. API-59CJ-OMe inhibits this pathway, inducing apoptosis in cancer cells with high AKT activity, suggesting therapeutic potential.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • PTEN (phosphatase and tensin homolog deleted on chromosome 10) is a tumor suppressor frequently mutated in endometrial cancers.
  • PTEN normally inhibits the AKT pathway, which plays a role in cell survival and apoptosis.
  • Dysregulation of the PTEN-AKT pathway is implicated in various cancers, including endometrial cancer.

Purpose of the Study:

  • To investigate the role of PTEN mutations and AKT activation in endometrial cancer cell lines.
  • To evaluate the efficacy of API-59CJ-OMe, an AKT pathway inhibitor, in preclinical models of endometrial cancer.

Main Methods:

  • Analysis of PTEN status and AKT phosphorylation/activity in four endometrial cancer cell lines (Ishikawa, RL95-2, Hec1A, KLE).
  • Treatment of these cell lines with API-59CJ-OMe.
  • Assessment of API-59CJ-OMe's effects on AKT kinase activity and induction of apoptosis.

Main Results:

  • Endometrial cancer cell lines with PTEN mutations (Ishikawa, RL95-2) exhibited high phosphorylated AKT levels and kinase activity.
  • Cell lines with wild-type PTEN (Hec1A, KLE) showed low AKT activity.
  • API-59CJ-OMe effectively inhibited AKT kinase activity and induced apoptosis in PTEN-mutated cell lines with high AKT activity.
  • API-59CJ-OMe had minimal impact on cell lines with wild-type PTEN and low AKT activity.

Conclusions:

  • Endometrial cancers with PTEN mutations are characterized by activated AKT signaling.
  • API-59CJ-OMe demonstrates preclinical efficacy by inhibiting AKT and promoting apoptosis in PTEN-mutated endometrial cancer cells.
  • API-59CJ-OMe holds potential as a targeted therapy for endometrial cancers harboring PTEN mutations and AKT activation.

More Related Videos

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics06:00

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics

Published on: May 14, 2016

11.6K
Using Mouse Mammary Tumor Cells to Teach Core Biology Concepts: A Simple Lab Module10:39

Using Mouse Mammary Tumor Cells to Teach Core Biology Concepts: A Simple Lab Module

Published on: June 18, 2015

13.9K

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.1K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
5.8K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
8.2K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.9K